These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26057506)

  • 1. Novel psoriasis therapies and patient outcomes, part 2: biologic treatments.
    Feely MA; Smith BL; Weinberg JM
    Cutis; 2015 May; 95(5):282-90. PubMed ID: 26057506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
    Krueger G; Callis K
    Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
    J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
    Mortel MR; Emer J
    J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword.
    Gottlieb AB
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel psoriasis therapies and patient outcomes, part 1: topical medications.
    Feely MA; Smith BL; Weinberg JM
    Cutis; 2015 Mar; 95(3):164-8, 170. PubMed ID: 25844785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.
    Weitz JE; Ritchlin CT
    Expert Opin Biol Ther; 2014 Apr; 14(4):515-26. PubMed ID: 24555741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel psoriasis therapies and patient outcomes, Part 3: Systemic medications.
    Feely MA; Smith BL; Weinberg JM
    Cutis; 2015 Jul; 96(1):47-53. PubMed ID: 26244353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept for psoriasis: two case reports.
    Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
    Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-alpha inhibitors in dermatology.
    Cordoro KM; Feldman SR
    Skin Therapy Lett; 2007 Sep; 12(7):4-6. PubMed ID: 17940711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J; Goldenberg G
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of biologics with traditional agents in psoriasis.
    Guenther LC
    Skin Therapy Lett; 2011 Jun; 16(6):1-3. PubMed ID: 21833461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
    Cho YT; Chen CH; Chiu HY; Tsai TF
    J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.
    Tan WS; Kelly S; Pitzalis C
    Expert Rev Clin Immunol; 2017 Mar; 13(3):207-222. PubMed ID: 27690678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.